{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T04:04:13Z","timestamp":1772510653169,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To investigate the independent contributions of glycated haemoglobin (HbA1c) reduction and weight loss to clinical outcomes in patients with type 2 diabetes (T2D) treated with antidiabetic drugs, including glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101RAs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This observational, retrospective cohort study used deidentified electronic health record\u2010derived data from patients evaluated at the Cleveland Clinic (1 January 2000\u201331 December 2020). Cohort A included 8876 patients with newly diagnosed T2D treated with any of six antidiabetic drug classes. Cohort B included 4161 patients with T2D initiating GLP\u20101RA treatment. The effects of body mass index (BMI) and HbA1c reduction, variability, and durability on clinical outcomes were investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In Cohort A, each 1% BMI reduction was associated with 3%, 1%, and 4% reduced risk of heart failure (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017), hypertension (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006), and insulin initiation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), respectively. Each 1% (~11 mmol\/mol) HbA1c\u00a0reduction was associated with 4% and 29% reduced risk of hypertension (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041) and insulin initiation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), respectively. In Cohort B, each 1% BMI reduction was associated with 4% and 3% reduced risk of cardiovascular disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008) and insulin initiation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), respectively. Each 1% (~11 mmol\/mol) HbA1c reduction was associated with 4% and 16% reduced risk of chronic kidney disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014) and insulin initiation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20091\u2009\u00d7\u200910\n                      <jats:sup>\u22124<\/jats:sup>\n                      ), respectively. Lower BMI variability and greater BMI durability were associated with decreased risk of clinical outcomes in both cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antidiabetic medication\u2010associated, and specifically GLP\u20101RA\u2010associated, weight loss and HbA1c reductions independently reduce real\u2010world clinical outcome risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15896","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:49:43Z","timestamp":1724806183000},"page":"5347-5357","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes"],"prefix":"10.1111","volume":"26","author":[{"given":"Anukriti","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Quantitative Health Sciences Lerner Research Institute, Cleveland Clinic  Cleveland Ohio USA"},{"name":"Center for Quantitative Metabolic Research Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshiya","family":"Mariam","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences Lerner Research Institute, Cleveland Clinic  Cleveland Ohio USA"},{"name":"Center for Quantitative Metabolic Research Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Zacherle","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.  Plainsboro New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Milinovich","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences Lerner Research Institute, Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine","family":"Bauman","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences Lerner Research Institute, Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Sugano","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences Lerner Research Institute, Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josh","family":"Noone","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.  Plainsboro New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigar R.","family":"Rajpura","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.  Plainsboro New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Institute Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartolome","family":"Burguera","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Institute Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Kattan","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences Lerner Research Institute, Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita D.","family":"Misra\u2010Hebert","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences Lerner Research Institute, Cleveland Clinic  Cleveland Ohio USA"},{"name":"Healthcare Delivery and Implementation Science Center Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3897-4551","authenticated-orcid":false,"given":"Kevin M.","family":"Pantalone","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Institute Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0553-3220","authenticated-orcid":false,"given":"Daniel M.","family":"Rotroff","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences Lerner Research Institute, Cleveland Clinic  Cleveland Ohio USA"},{"name":"Center for Quantitative Metabolic Research Cleveland Clinic  Cleveland Ohio USA"},{"name":"Endocrinology and Metabolism Institute Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.10.1499"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2415"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14538"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903081725"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2217\/thy.11.8"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2011.158"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7771"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"e_1_2_10_16_1","unstructured":"A heart disease study of semaglutide in patients with type 2 diabetes (SOUL).ClinicalTrials.gov identifier: NCT03914326.2023. Accessed March 27 2023https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03914326"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12969"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/amiajnl-2011-000439"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32131-2"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(01)00297-2"},{"key":"e_1_2_10_22_1","unstructured":"R Core Team.R: a language and environment for statistical computing. R Foundation for Statistical Computing.https:\/\/www.R-project.org"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S116810"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13221"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1914"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.162"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0323-4"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-018-3416-4"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-0784"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0055"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S51325"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2009.10.001"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02153-x"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01710-0"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4020492"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6324348"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.09.004"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5568159"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S405327"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012305"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad282"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:03:57Z","timestamp":1761861837000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/dom.15896"],"URL":"https:\/\/doi.org\/10.1111\/dom.15896","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"2024-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}